Immunotoxins

• 

  Subject Areas on Research

  • A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast-cancer cell lines. 
  • A comprehensive outlook on intracerebral therapy of malignant gliomas. 
  • A reevaluation of CD22 expression in human lung cancer. 
  • Activation of T lymphocytes for adhesion and cytokine expression by toxin-conjugated anti-CD3 monoclonal antibodies. 
  • Additive and synergistic interactions of monoclonal antibodies and immunotoxins reactive with breast and ovarian cancer. 
  • Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas. 
  • Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas. 
  • Analysis of primate renal allografts after T-cell depletion with anti-CD3-CRM9. 
  • Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. 
  • Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. 
  • Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). 
  • Antitransferrin receptor immunotoxin inhibits proliferating human retinal pigment epithelial cells. 
  • Autocrine growth factors and neuroendocrine markers in the development of small-cell lung cancer. 
  • Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent. 
  • Clearance of antitransferrin receptor immunotoxin from the rabbit eye. 
  • Clinical immunotherapy for brain tumors. 
  • Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. 
  • Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. 
  • Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. 
  • EGF mutant receptor vIII as a molecular target in cancer therapy. 
  • EGFRvIII as a promising target for antibody-based brain tumor therapy. 
  • EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells. 
  • Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis. 
  • Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'-deoxycoformycin, deoxyadenosine and an immunotoxin. 
  • Enhanced pancreatic cancer gene therapy by combination of adenoviral vector expressing c-erb-B2 (Her-2/neu)-targeted immunotoxin with a replication-competent adenovirus or etoposide. 
  • Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate. 
  • Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. 
  • FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. 
  • Graft survival in a rhesus renal transplant model after immunotoxin-mediated T-cell depletion is enhanced by mycophenolate and steroids. 
  • Imaging of convection enhanced delivery of toxins in humans. 
  • Immune status assay (ISA): a noninvasive procedure for studying allograft rejection. 
  • Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. 
  • Immunotoxin FN18-CRM9 induces stronger T cell signaling than unconjugated monoclonal antibody FN18. 
  • Immunotoxin Therapy for Lung Cancer. 
  • Immunotoxin-treated rhesus monkeys: a model for renal allograft chronic rejection. 
  • Immunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome. 
  • Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. 
  • Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display. 
  • Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation. 
  • Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. 
  • Increased glomerular deposits of von Willebrand factor in chronic, but not acute, rejection of primate renal allografts. 
  • Inducing unresponsiveness by the use of anti-CD3 immunotoxin, CTLA4-Ig, and anti-CD40 ligand. 
  • Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin. 
  • Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238. 
  • Inhibition of human corneal epithelium with immunotoxin 454A12-rRA. 
  • Inhibition of human subconjunctival fibroblast proliferation by immunotoxin. 
  • Inhibition of proliferating lens epithelium with antitransferrin receptor immunotoxin. 
  • Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. 
  • Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model. 
  • Involvement of protein tyrosine phosphorylation in immunotoxin effects on T lymphocytes. 
  • Mechanisms of tolerance induced by an immunotoxin against CD3 epsilon in a rhesus kidney allograft model. 
  • Monensin enhances the cytotoxic effect of antitransferrin receptor immunotoxin on cultured RPE cells. 
  • Monoclonal antibodies for brain tumour treatment. 
  • Monoclonal antibody therapy for malignant glioma. 
  • Monoclonal antibody therapy in the treatment of non-Hodgkin lymphoma. 
  • N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate: synthesis and potential utility for the radioiodination of monoclonal antibodies. 
  • Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy. 
  • Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. 
  • Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. 
  • Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats. 
  • Primate renal transplants using immunotoxin. 
  • Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial. 
  • Radioiodination of antibodies via N-succinimidyl 2,4-dimethoxy-3-(trialkylstannyl)benzoates. 
  • Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis. 
  • Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system. 
  • Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo. 
  • Recombinant immunotoxin containing a disulfide-stabilized Fv directed at erbB2 that does not require proteolytic activation. 
  • Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. 
  • Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1. 
  • Reversal of acute allograft rejection using immunotoxin. 
  • SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies. 
  • Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. 
  • Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. 
  • Split tolerance induced by immunotoxin in a rhesus kidney allograft model. 
  • Strategies for tolerance induction in nonhuman primates. 
  • Suppression of human corneal epithelial proliferation with breast carcinoma immunotoxin. 
  • Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors. 
  • Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. 
  • The antiproliferative effect of a transferrin-toxin on human retinal pigment epithelial cells and rabbit fibroblasts. 
  • The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro. 
  • The effects of local hyperthermia on the catabolism of a radioiodinated chimeric monoclonal antibody. 
  • Tolerance and near-tolerance strategies in monkeys and their application to human renal transplantation. 
  • Toxin-based targeted therapy for malignant brain tumors. 
  • Treatment with immunotoxin. 
  • Use of immunotoxins in combination to inhibit clonogenic growth of human breast carcinoma cells. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology